First Time Loading...

Consun Pharmaceutical Group Ltd
HKEX:1681

Watchlist Manager
Consun Pharmaceutical Group Ltd Logo
Consun Pharmaceutical Group Ltd
HKEX:1681
Watchlist
Price: 6.91 HKD -1% Market Closed
Updated: May 20, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Balance Sheet

5.5B
+10%
Assets
Growth Rates:
1 Year
+13%
3 Years
+39%
5 Years
+41%
7 Years
+100%
10 Years
+278%
1.9B
+9%
Liabilities
Growth Rates:
1 Year
+8%
3 Years
+9%
5 Years
+8%
7 Years
+88%
10 Years
+843%
3.6B
+10%
Equity
Growth Rates:
1 Year
+15%
3 Years
+63%
5 Years
+68%
7 Years
+106%
10 Years
+188%

Balance Sheet Decomposition
Consun Pharmaceutical Group Ltd

5.5B
Assets
1.9B
Liabilities
5.5B
Assets
1.9B
Liabilities
Current Assets 4.3B
Cash & Short-Term Investments 3.6B
Receivables 310m
Other Current Assets 384.9m
Non-Current Assets 1.2B
Long-Term Investments 23.9m
PP&E 739.1m
Intangibles 283.1m
Other Non-Current Assets 183.9m
Current Liabilities 1.5B
Accounts Payable 942.4m
Short-Term Debt 503.4m
Other Current Liabilities 49.1m
Non-Current Liabilities 386.5m
Long-Term Debt 3.9m
Other Non-Current Liabilities 382.6m

Balance Sheet
Consun Pharmaceutical Group Ltd

Rotate your device to view
Balance Sheet
Currency: CNY
Dec-2014 Dec-2015 Dec-2016 Dec-2017 Dec-2018 Dec-2019 Dec-2020 Dec-2021 Dec-2022 Dec-2023
Assets
Cash & Cash Equivalents
844
490
673
990
1 270
1 383
1 940
2 196
2 450
2 748
Cash
0
0
0
0
0
0
0
0
2 450
0
Cash Equivalents
844
490
673
990
1 270
1 383
1 940
2 196
0
2 748
Short-Term Investments
0
0
0
0
0
0
0
230
589
835
Total Receivables
244
386
566
986
884
792
458
370
296
310
Accounts Receivables
232
364
557
970
864
764
449
351
260
310
Other Receivables
12
23
9
16
20
28
10
18
36
0
Inventory
53
71
141
200
210
211
227
243
276
367
Other Current Assets
5
13
10
9
32
23
33
17
12
18
Total Current Assets
1 397
960
1 390
2 185
2 396
2 410
2 659
3 056
3 623
4 278
PP&E Net
230
224
393
401
562
661
676
725
746
739
PP&E Gross
230
224
393
401
562
661
676
725
746
0
Accumulated Depreciation
78
88
107
135
170
205
241
273
307
0
Intangible Assets
0
0
490
460
431
396
371
342
312
283
Goodwill
0
0
321
321
321
0
0
0
0
0
Long-Term Investments
3
639
21
20
17
17
16
16
22
24
Other Long-Term Assets
34
95
145
185
170
224
228
225
190
184
Other Assets
0
0
321
321
321
0
0
0
0
0
Total Assets
1 663
N/A
1 918
+15%
2 759
+44%
3 572
+29%
3 897
+9%
3 708
-5%
3 950
+7%
4 363
+10%
4 892
+12%
5 508
+13%
Liabilities
Accounts Payable
36
40
80
69
93
56
51
67
60
942
Accrued Liabilities
73
95
237
412
446
365
406
466
566
0
Short-Term Debt
0
0
0
0
0
0
549
599
451
503
Current Portion of Long-Term Debt
0
0
0
194
147
554
0
3
4
4
Other Current Liabilities
69
95
230
296
313
323
325
223
270
45
Total Current Liabilities
178
229
547
970
999
1 296
1 332
1 357
1 350
1 495
Long-Term Debt
0
0
0
374
245
0
0
9
6
4
Deferred Income Tax
39
40
130
142
137
88
86
69
78
71
Minority Interest
0
0
301
317
340
313
296
293
294
292
Other Liabilities
12
12
22
21
18
17
16
17
19
19
Total Liabilities
230
N/A
281
+22%
999
+255%
1 825
+83%
1 740
-5%
1 714
-1%
1 730
+1%
1 745
+1%
1 747
+0%
1 881
+8%
Equity
Common Stock
78
78
76
69
69
68
64
65
63
64
Retained Earnings
670
911
1 230
1 430
1 900
1 778
2 154
2 561
3 080
3 563
Additional Paid In Capital
685
648
454
247
188
145
0
20
0
0
Treasury Stock
0
0
0
0
0
0
0
30
0
0
Other Equity
0
0
0
0
0
3
2
2
2
0
Total Equity
1 433
N/A
1 637
+14%
1 760
+8%
1 747
-1%
2 157
+24%
1 994
-8%
2 220
+11%
2 618
+18%
3 145
+20%
3 627
+15%
Total Liabilities & Equity
1 663
N/A
1 918
+15%
2 759
+44%
3 572
+29%
3 897
+9%
3 708
-5%
3 950
+7%
4 363
+10%
4 892
+12%
5 508
+13%
Shares Outstanding
Common Shares Outstanding
1 000
998
974
874
875
866
820
824
807
811

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 138,800+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.